TABLE 1.
Characteristics of 16 persons with acute‐onset polyradiculoneuropathy within 4 wk of any first dose of SARS‐CoV2 vaccination
| Mean age (SD) (y) | 57.2 (9.5) |
| Gender distribution | 9 males, 7 females |
| Vaccine exposure | |
| AstraZeneca | 14 (87.5%) |
| Pfizer | 1 (6.3%) |
| Moderna | 1 (6.3%) |
| Clinical subtype | |
| Classic GBS | 12 (75%) |
| Bifacial weakness and distal paresthesias | 3 (18.8%) |
| Pharyngocervicobrachial variant | 1 (6.3%) |
| Clinical features | |
| Motor weakness | 14 (87.5%) |
| Hypo/areflexia | 13 (81.3%) |
| Facial weakness | 9 (56.3%) |
| Bulbar weakness | 8 (50%) |
| Dysautonomia | 1 (6.3%) |
| Electrophysiological subtype | |
| AIDP | 11 (68.8%) |
| Axonal | 1 (6.3%) |
| Equivocal | 1 (6.3%) |
| Normal | 1 (6.3%) |
| Not done | 2 (12.5%) |
| Mean CSF protein (SD) (mg/dl) | 180 (115) |
| Antiganglioside antibody positivity | 0/8 (0%) |
| ICU admission | 4 (25%) |
| Mechanical ventilation | 3 (18.8%) |
| Ability to walk unaided at discharge | 8 (50%) |
| In‐hospital mortality | 1 (6.3%) |
Abbreviation: AIDP, acute inflammatory demyelinating polyneuropathy.